|
Recruiting
|
NCT06019468 -
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
|
Phase 2 |
|
Terminated
|
NCT00818090 -
Paclitaxel and Cisplatin for Thymic Neoplasm
|
Phase 2 |
|
Completed
|
NCT02623127 -
A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
|
Phase 2 |
|
Active, not recruiting
|
NCT03921671 -
Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
|
Phase 2 |
|
Active, not recruiting
|
NCT02364076 -
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
|
Phase 2 |
|
Terminated
|
NCT01100944 -
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
|
Phase 1/Phase 2 |
|
Recruiting
|
NCT03449173 -
Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)
|
Phase 2 |
|
Recruiting
|
NCT03556228 -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
|
Phase 1 |
|
Completed
|
NCT01364727 -
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
|
Phase 2 |
|
Suspended
|
NCT03463460 -
Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer
|
Phase 2 |
|
Completed
|
NCT00010257 -
Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma
|
Phase 2 |
|
Completed
|
NCT04430842 -
Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S
|
Phase 1 |
|
Active, not recruiting
|
NCT03583086 -
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
|
Phase 1/Phase 2 |
|
Completed
|
NCT03517488 -
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
|
Phase 1 |
|
Completed
|
NCT00198133 -
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
|
Phase 2 |
|
Recruiting
|
NCT03170804 -
Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer
|
N/A |
|
Terminated
|
NCT01011439 -
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
|
Phase 2 |
|
Terminated
|
NCT01143545 -
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
|
Phase 1 |
|
Completed
|
NCT02307500 -
Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy
|
Phase 2 |
|
Active, not recruiting
|
NCT01025089 -
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
|
Phase 2 |